Personal Information
Entreprise/Lieu de travail
Greater New York City Area, NY United States
Profession
CEO at IMMUNE Pharmaceuticals
Secteur d’activité
Medical / Health Care / Pharmaceuticals
Site Web
http://www.21westpartners.com
À propos
Founder and CEO of IMMUNE Pharmaceuticals, Grew into a NASDAQ listed company in 3 years. IMMUNE focuses on Antibody Therapeutics with a lead phase II first in class mAb, bertilimumab, for the treatment of inflammatory diseases, including Crohn's and Colitis and Bullous Pemphigoid, an auto-immune orphan disease of the skin. Pipeline includes Amiket, a drug with Orphan Drug Designation for the treatment of Post Herpetic Neurlalgia. Immune is seeking a development and commercialization partner for Amiket. Immune NanomAb platform, developed with the Hebrew University of Jerusalem, is the next generation of "guided therapeutic missiles" targeting specifically cancer cells through a three step ...